TP53 and acute myeloid leukemia: These findings suggest that selinexor single-agent activity in AML is dependent, at least in part, on minimally one functional TP53 allele (Nishida et al., 2019), as shown for other tumor types, including diffuse large B-cell lymphoma (DLBCL) and gastric cancer (Deng et al., 2020; Subhash et al., 2018).